HCW Biologics Inc. (NASDAQ:HCWB) Sees Large Decline in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 13,416 shares, a decrease of 78.6% from the December 15th total of 62,738 shares. Based on an average daily trading volume, of 65,324 shares, the short-interest ratio is presently 0.2 days. Approximately 0.8% of the shares of the company are short sold. Approximately 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 65,324 shares, the short-interest ratio is presently 0.2 days.

HCW Biologics Price Performance

Shares of HCWB stock remained flat at $1.15 during trading on Thursday. 22,520 shares of the company traded hands, compared to its average volume of 43,065. The business’s 50 day simple moving average is $1.86 and its 200-day simple moving average is $3.42. The firm has a market cap of $3.77 million, a PE ratio of -0.10 and a beta of 0.71. HCW Biologics has a one year low of $0.95 and a one year high of $41.20.

HCW Biologics (NASDAQ:HCWB) last announced its earnings results on Friday, November 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.58 by ($3.60). The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $7.00 million.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC purchased a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned 0.69% of HCW Biologics as of its most recent SEC filing. 2.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, HCW Biologics has a consensus rating of “Hold” and a consensus target price of $35.00.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.